MedTrace Logo

Minimally Invasive Sensing of Beta-lactam Antibiotics

NCT03847610 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-03-27

Study results available
· View outcomes & findings →

Summary

This study is an in-house feasibility study of a microneedle biosensor developed within Imperial College London.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Phenoxymethyl Penicillin

Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study

DEVICE

Microneedle array

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alison H Holmes, MD MPH MBBS · Health Protection Research Unit in HCAI & AMR

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2018-08-10
Completion
2018-08-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03847610 on ClinicalTrials.gov